miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer

• Published in: Breast cancer research : BCR Vol. 27; no. 1; pp. 90 - 14
• Main Authors: Spychalski, Griffin B., Lin, Andrew A., Yang, Stephanie J., Shen, Hanfei, Rosario, Jean, Tien, Kyle, French, Kate, Ghali, Miriyam, Yee, Stephanie, Yin, Melinda, Feldman, Michael D., Conant, Emily F., Weinstein, Susan P., Carpenter, Erica L., Issadore, David, Nayak, Anupma
• Format: Journal Article
• Language: English
• Published: London BioMed Central 22.05.2025; BioMed Central Ltd; BMC
• Subjects: Adult; Aged; BI-RADS 4 breast lesions; Biological markers; Biomarkers; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Biomedical and Life Sciences; Biomedicine; Biopsy; Breast cancer; Breast Neoplasms - blood; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer; Cancer Research; Carcinoma; CD24 Antigen - genetics; CD24 Antigen - metabolism; Classification; Diagnosis; Early detection biomarkers; Early Detection of Cancer - methods; ErbB-2 protein; Ethylenediaminetetraacetic acid; Extracellular vesicles; Extracellular Vesicles - genetics; Extracellular Vesicles - metabolism; Female; Humans; Hyperplasia; Immunohistochemistry; Invasiveness; Lesions; Liquid Biopsy; Malignancy; Mammography; Metastases; MicroRNA; MicroRNAs; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; miRNA; MiRNA sequencing; Neoplasm Staging; Next-generation sequencing; Oncology; Pathology; Patients; Plasma; Prospective Studies; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Subpopulations; Surgical Oncology; United States > US; Early detection biomarkers; Extracellular vesicles; Liquid biopsy; MiRNA sequencing; BI-RADS 4 breast lesions
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-025-02029-2

Background Mammography screening has improved early breast cancer detection, leading to reduced mortality and lower rates of advanced breast cancer. However, mammography has a high false positive rate that results in over a million invasive breast biopsies of benign lesions in the US each year. Therefore, there is a need for noninvasive, blood-based diagnostics that can accurately assess risk of malignancy for women with indeterminate lesions identified by mammography, such as BI-RADS category 4 breast lesions. The aim of this study is to identify biomarkers from multiplexed extracellular vesicle liquid biopsy that can accurately classify mammographically detected BI-RADS 4 lesions. Methods We analyzed plasma from 113 prospectively enrolled subjects with BI-RADS 4 breast lesions, including 86 women with benign lesions and 27 women with malignant lesions (including 12 with stage I invasive carcinoma and 14 with ductal carcinoma in situ ). None of the invasive carcinomas were metastatic. From each plasma sample, we used track etched magnetic nanopore technology to separately isolate HER2 and CD24 expressing extracellular vesicles (EVs) and measured their miRNA cargo using next-generation sequencing. We evaluated the performance of EV-miRNA biomarkers for classifying malignancy and applied LASSO classification to identify a panel of four complementary EV miRNA biomarkers that we validated by qPCR. Results We identified 19 differentially enriched miRNA from HER2+ EVs and 11 differentially enriched miRNA from CD24+ EVs of women with malignant lesions compared to benign lesions. We observed individual miRNA with an AUC of up to 0.87 for miR-340-5p from HER2+ EVs and 0.75 for miR-223-3p from CD24+ EVs. LASSO classification selected a panel of four complementary EV miRNA for classifying breast cancer: miR-340-5p (HER2+ EVs), miR-598-3p (CD24+), miR-15b-5p (HER2+), and miR-126-3p (CD24+). Conclusions HER2+ and CD24+ EV subpopulations contain complementary biomarkers suitable for validation in larger studies that can accurately detect early-stage breast cancer among women with BI-RADS category 4 breast lesions.